# US 2026/0242393 A1 · Preparation Method for and Use of Dihydrothienopyrimidine Derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242393 A1
- Document ID: US20260242393A1
- Status: Published application
- Kind: A1
- Application number: 19/160,446
- Filed: 2024-02-28
- Published: 2026-08-20
- Earliest claimed: 2023-02-28
- Assignees: Innovstone Therapeutics Limited
- Applicants: Innovstone Therapeutics Limited
- Inventors: Yunlong SONG; Feng WANG; Pengpeng WANG; Yongzhao Mu; Disha WANG; Hongyan KOU; Ning YU; Kai LU; Xiang LEI; Dengyun XU; Jian CHEN; Wei LI; Kun ZHANG; Xingxing XIE
- Web page: https://patentgrep.com/patent/US20260242393A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 495/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/04: for throat disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07B 59/002: {Heterocyclic compounds}
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention provides a compound having a new structure as a PDE4B inhibitor, a preparation method for the compound, and a use of the compound in treating PDE4B-mediated diseases. Experiments confirm that the compound has a strong inhibitory effect on PDE4B enzyme and can be used as a promising compound for treating PDE4B-mediated diseases.

## Claims

### Claim 1

A compound represented by formula (I), a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound:
wherein, X is selected from S, SO, and SO2;
Y is NRY;
RY is hydrogen or deuterium;
ring Q is selected from C3-8cycloalkyl, C4-8cycloalkenyl, 3-10 membered heterocyclyl, 5-6 membered heteroaryl, and C6-12 aryl;
each RQ is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, phosphate, carboxylate, —CN, —OH, —SH, —NO2, —NH2, —CONH2,
-LY-OH, -LY-SH, -LY-C(O)OH, -LY-NH—C(O)H, -LY-C(O)NH2, -LY-NHC(O)OH, -LY-C(O)H,
C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-6cycloalkyl, C4-6-cycloalkenyl, 3-6 membered heterocyclyl, haloC1-6alkyl (e.g. haloC1-3alkyl), -LY-OC(O)Rd, and -LY-OC(O)ORd; preferably, each RQ is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, phosphate, carboxylate, —CN, —OH, —SH, —NO2, —NH2, —CONH2,
-LY-OH, -LY-SH, -LY-C(O)OH, -LY-NH—C(O)H, -LY-C(O)NH2, -LY-NHC(O)OH, -LY-C(O)H,
C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-6cycloalkyl, C4-6cycloalkenyl, 3-6 membered heterocyclyl, haloC1-6alkyl (e.g. haloC1-3alkyl), and -LY-OC(O)Rd; more preferably, each RQ is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, phosphate, carboxylate, —CN, —OH, —SH, —NO2, —NH2, —CONH2,
-LY-OH, -LY-SH, -LY-C(O)OH, -LY-NH—C(O)H, -LY-C(O)NH2, -LY-NHC(O)OH, -LY-C(O)H,
C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-6cycloalkyl, C4-6-cycloalkenyl, 3-6 membered heterocyclyl, and haloC1-6alkyl (e.g. haloC1-3alkyl);
LY is optionally substituted and selected from C1-4alkylene, C2-6alkenylene, C2-6alkynylene, and C1-4alkyleneoxy, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, oxo, —CN, —OH, —SH, —NO2, —NH2, C1-3alkyl, and haloC1-3alkyl;
L is a bond or an optionally substituted group selected from C1-4alkylene, C2-4alkenylene, C2-4 alkynylene, and C1-4alkyleneoxy, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, halogen, oxo, —CN, —OH, —SH, —NO2, —NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-8cycloalkyl, and haloC1-6alkyl;
ring W is C4-16cycloalkyl, C4-16cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclyl, 5-16 membered heteroaryl, or C6-18 aryl;
each RW is independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetylamino, —CN, —OH, —SH, —NO2, —NH2, —CONH2, —Z—(RZ)m, —NRbRc, —C(O)ORd, and an optionally substituted group selected from C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, and C1-6alkylthio, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, halogen, oxo, oxime, —CN, —OH, —SH, —NO2, —NH2, —C(O)ORd, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-8cycloalkyl, C3-8cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C6-12 aryl, haloC1-6alkyl, haloC1-6alkoxyl, halophenyl, and —O—C3-6 cycloalkyl; Rb and Rc are each independently selected from H, C1-6alkyl, C2-6alkenyl, C1-6 hydroxyalkyl, and haloC1-6alkyl; Rd is selected from H, C1-6alkyl, C1-6hydroxyalkyl, haloC1-6alkyl, and C1-6alkylamino; preferably, each RW is independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetylamino, —CN, —OH, —SH, —NO2, —NH2, —CONH2, —Z—(RZ)m, —NRbRc, —C(O)ORd, and an optionally substituted group selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, and C1-6alkylthio, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, halogen, oxo, oxime, —CN, —OH, —SH, —NO2, —NH2, —C(O)ORd, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-8cycloalkyl, C3-8cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C6-12 aryl, haloC1-6alkyl, haloC1-6alkoxyl, halophenyl, and —O—C3-6cycloalkyl; Rb and Rc are each independently selected from H, C1-6alkyl, C2-6alkenyl, C1-6 hydroxyalkyl, and haloC1-6alkyl; Rd is selected from H, C1-6alkyl, C1-6hydroxyalkyl, and haloC1-6alkyl; more preferably, each RW is independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, —CN, —OH, —SH, —NO2, —NH2, —CONH2, —Z—(RZ)m, and an optionally substituted group selected from C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6alkoxyl, and C1-6alkylthio, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, oxo, oxime, —CN, —OH, —SH, —NO2, —NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-8cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C6-12 aryl, haloC1-6alkyl, haloC1-6alkoxyl, halophenyl, and —O—C3-6cycloalkyl;
Z is C4-16cycloalkyl, C4-16cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclyl, 5-16 membered heteroaryl, or C6-12 aryl;
RZ is each independently selected from halogen, —CN, —OH, —SH, —NO2, —NH2, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6hydroxyalkyl, haloC1-6alkyl, haloC1-6alkoxyl, saturated or partially unsaturated 4-6 membered heterocyclyl, —ORZ1, and —NRZ2RZ3; RZ1 is selected from C1-6alkyl and haloC1-6alkyl; RZ2 and RZ3 are each independently selected from H and C1-6alkyl;
preferably, RZ is each independently selected from halogen, —CN, —OH, —SH, —NO2, —NH2, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6hydroxyalkyl, haloC1-6alkyl, and haloC1-6alkoxyl; more preferably, RZ is each independently selected from halogen, —CN, —OH, —SH, —NO2, —NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6hydroxyalkyl, haloC1-6alkyl, and haloC1-6alkoxyl;
n is 0, 1, 2, 3, 4 or 5;
q is 0, 1, 2, 3, 4 or 5;
m is 0, 1, 2, 3, 4 or 5;
provided that:
(1) when L is a bond,
is neither
(2) when L is a bond, and
RW is neither a substituted phenyl nor
(3) when X is SO, and L is a bond,
is not any of
preferably, when X is SO, and L is a bond
is not any of
(4) when X is S or SO2, and L is a bond, ring Q and ring W are not a substituted phenyl at the same time; or when X is S, L is a bond, and ring Q is phenyl, ring W is not
(5) when X is S or SO2, and L is a bond, ring Q is not
The heteroatoms in the heterocyclyl and heteroaryl are independently selected from O, N and S, and the number of heteroatoms is preferably 1, 2 or 3.

### Claim 2 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by any of formulae (I-A), (I-B) and (I-C):
wherein, X, q, RQ, ring Q, n, RW, and ring W are as defined in claim 1.

### Claim 3 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by any of formulae (II-A) to (II-E):
wherein X, n, RW, ring W, RQ, and q are as defined in claim 1.

### Claim 4 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by any of formulae (III-A) to (III-H):
wherein, n, RW, ring W, RQ, and q are as defined in claim 1, S* is a chiral sulfur atom, preferably in R configuration.

### Claim 5 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by any of formulae (IV-A) to (IV-E):
wherein, n, RW, and ring W are as defined in claim 1, S* is a chiral sulfur atom, preferably in R configuration.

### Claim 6 (depends on 1)

The compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein
RY is deuterium; or RY is hydrogen; and/or
ring Q is selected from C4-6cycloalkyl, C4-6cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, and phenyl;
preferably, ring Q is selected from C4-6cycloalkyl, 3-6 membered heterocyclyl, and phenyl;
more preferably, ring Q is selected from cyclobutyl, cyclohexenyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, phenyl, and tetrahydropyranyl;
most preferably, ring Q is phenyl or tetrahydropyranyl; and/or
each RQ is independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, phosphate, carboxylate, —CN, —OH, —SH, —NO2, —NH2, —CONH2,
-LY-OH, -LY-C(O)OH, -LY-C(O)H,
C1-3alkyl, C2-4alkenyl, C2-4alkynyl, C1-3alkoxyl, C1-3alkylthio, C3-6cycloalkyl, C3-6cycloalkenyl, 3-6 membered heterocyclyl, haloC1-3alkyl, and -LY-OC(O)Rd;
preferably, each RQ is independently selected from halogen, oxo, acetyl,
-LY-OH, -LY-C(O)OH, C1-3alkyl, C3-6cycloalkyl, 3-6 membered heterocyclyl, and -LY-OC(O)Rd;
more preferably, each RQ is independently selected from halogen, oxo, acetyl,
-LY-OH, -LY-C(O)OH, C1-3alkyl, C3-6cycloalkyl, and -LY-OC(O)Rd;
most preferably, each RQ is independently selected from hydroxymethyl, carboxymethyl, acetyl,
hydroxyisopropyl, Cl, oxo, cyclopropyl, and
and/or
LY is optionally substituted and selected from C1-4alkylene, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, oxo, —CN, —OH, —SH, —NO2, —NH2, C1-3alkyl, and haloC1-3alkyl;
preferably, LY is optionally substituted and selected from C1-2alkylene, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, —OH, —SH, —NH2, C1-3alkyl, and haloC1-3alkyl;
more preferably, LY is optionally substituted and selected from methylene and ethylene, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, —OH, —SH, methyl, and ethyl; and/or
L is a bond or an optionally substituted group selected from: C1-3alkylene, C2-4alkenylene, and C2-4alkynylene, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, halogen, oxo, —CN, —OH, —SH, —NH2, C1-3alkyl, C2-4alkenyl, C2-4alkynyl, C1-3alkoxyl, C1-3alkylthio, C3-8cycloalkyl, and haloC1-3alkyl;
preferably, L is a bond or an optionally substituted group selected from: C2-4alkenylene and C2-4alkynylene, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, —CN, —OH, —SH, —NH2, and C1-3alkyl;
more preferably, L is a bond or an optionally substituted group selected from: ethenyl, propenyl, ethynyl, and propynyl, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, —CN, —OH, —SH, —NH2, and C1-3alkyl;
most preferably, L is a bond; or L is ethynyl; or L is an optionally substituted propynyl, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from deuterium, —CN, —OH, —SH, —NH2, and C1-3alkyl; and/or
ring W is C4-12cycloalkyl, C4-12cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclyl, 5-16 membered heteroaryl, or C6-12 aryl;
preferably, ring W is C4-5monocyclic cycloalkyl, C5-10bicyclic cycloalkyl, C4-8 monocyclic cycloalkenyl, C7-10bicyclic cycloalkenyl, saturated or partially unsaturated 4-8 membered monocyclic heterocyclyl, saturated or partially unsaturated 7-12 membered bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 9-16 membered bicyclic heteroaryl, phenyl, or naphthyl;
more preferably, ring W is

### Claim 7 (depends on 1)

The compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein
preferably
or more preferably

### Claim 8 (depends on 1)

The compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein
each RW is independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, —CN, —OH, —SH, —NO2, —NH2, —CONH2, —Z—(RZ)m, an optionally substituted C1-6alkyl, and an optionally substituted C1-6alkoxyl, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, oxo, oxime, —CN, —OH, —SH, —NO2, —NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6alkylthio, C3-8cycloalkyl, C3-8cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C6-12 aryl, haloC1-6alkyl, haloC1-6alkoxyl, halophenyl, and —O—C3-6cycloalkyl;
Z is C4-10cycloalkyl, C4-10cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclyl, 5-12 membered heteroaryl, or C6-12 aryl;
RZ is each independently selected from halogen, —CN, —OH, —SH, —NO2, —NH2, C1-3alkyl, C2-6alkenyl, C2-6alkynyl, C1-3alkoxyl, C1-3hydroxyalkyl, haloC1-3alkyl, and haloC1-3alkoxyl;
preferably, each RW is independently selected from halogen, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, —CN, —OH, —SH, —NH2, —Z—(RZ)m, an optionally substituted C1-4alkyl, and an optionally substituted C1-4alkoxyl, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, —CN, —OH, —SH, —NO2, —NH2, C1-3alkyl, C1-3alkoxyl, C3-6cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C6-12 aryl, haloC1-3alkyl, haloC1-3alkoxyl, and halophenyl;
Z is pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, or phenyl;
RZ is each independently selected from halogen, —CN, —OH, —SH, —NO2, —NH2, C1-3alkyl, C1-3alkoxyl, C1-3hydroxyalkyl, haloC1-3alkyl, and haloC1-3alkoxyl.

### Claim 9 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by formula (IV-A) or (IV-E), preferably the compound is a compound represented by formula (IV-A):
wherein
each RW is independently selected from methylsulfonyl, methylsulfonamido, ethylsulfonamido, F, Cl, —CN, —OH, —SH, —NH2,
and an optionally substituted group selected from: methyl, ethyl, iso-propyl, methoxy, ethoxy, methylthio, and ethylthio, wherein “optionally substituted” refers to being optionally substituted by one or more substituents selected from halogen, —CN, —OH, —NH2, C1-3alkyl, C1-3alkoxyl, C1-3haloalkyl, and C1-3haloalkoxyl, preferably each RW is independently selected from methylsulfonyl, methylsulfonamido, ethylsulfonamido, F, Cl, —CN, —OH, —SH, —NH2,

### Claim 10 (depends on 1)

The compound of claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein the compound is a compound represented by formula (IV-A) or (IV-E), preferably the compound is a compound represented by formula (IV-A):
wherein
preferably
each RW is independently selected from
preferably, each RW is independently selected from

### Claim 11 (depends on 1)

The compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein
m is 0, 1, 2 or 3;
preferably, m is 1, 2 or 3;
more preferably, m is 1 or 2; and/or
n is 0, 1, 2 or 3;
preferably, n is 0, 1 or 2;
more preferably, n is 1 or 2; and/or
q is 0, 1, 2 or 3;
preferably, q is 0, 1 or 2;
more preferably, q is 1 or 2.

### Claim 12 (depends on 1)

The compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, wherein said compound is selected from:
No
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112

### Claim 13 (depends on 1)

A pharmaceutical composition, which contains a therapeutically effective amount of the compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method for treating and/or preventing a PDE4B-mediated disease, which method comprises administering to a subject in need thereof a therapeutically effective amount of the compound according to claim 1, a stereoisomer or tautomer of said compound, a mixture thereof, or a pharmaceutically acceptable salt of said compound, preferably said disease includes respiratory disease, gastrointestinal disease, inflammatory disease, allergic disease, autoimmune disease or cancer, for example:
said respiratory disease is selected from respiratory or pulmonary diseases accompanied by increased mucus production, airway inflammation and/or obstructive diseases; further preferably, said respiratory disease is selected from idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial pneumonia, chronic obstructive pulmonary disease (COPD), alpha-1 antitrypsin deficiency, chronic rhinosinusitis, asthma or chronic bronchitis;
said gastrointestinal disease is selected from regional ileitis, ulcerative colitis or Crohn's disease;
said inflammatory disease is selected from dry eye syndrome or glaucoma;
said autoimmune disease is selected from atopic dermatitis, seborrheic dermatitis, psoriasis, urticaria, multiple sclerosis and diffuse connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, polymyositis, vasculitis, and Sjogren's syndrome.
